STING agonist treatment increased NK cell migration in malignant pleural mesothelioma, correlating with increased tumor cell death.[38] Furthermore, a depletion of STING reduced NK cell recruitment and activation in NK cell‐sensitive tumors, such as B16D8 melanoma.[39] Additionally, STING activation promoted the secretion of the C‐X‐C motif chemokine receptor 3 (CXCR3)‐binding chemokine C‐X‐C motif chemokine ligand 9 (CXCL9) and CXCL10 as well as C‐C motif ligand 5 (CCL5) by tumor cells and CAFs, promoting NK and T cell recruitment (Figure 2).[16, 38] Interestingly, Wolf et al. The gene discussed is CXCR3; the disease is neoplasm.